The process of malignancy induction provides close insights into more general cellular functions through a group of potentially transforming genes, termed protooncogenes. Two such genes, neu and kit structurally resemble well-characterized receptors for growth/differentiation factors. Although their ligands and physiological roles are yet unknown, their biology suggests involvement in the regulation of growth of mesenchymal and secretory tissues (neu) and stem cell differentiation (kit). Here we propose a multi-approach study designed to provide mutually independent, and perhaps complementary information on the functional roles of the neu and kit-encoded receptors. First, a series of sensitive bioassays will be employed to detect and later also to isolate the putative polypeptide growth factors that bind to the presumed receptors. Second and in parallel, anti-receptor monoclonal antibodies will be generated. Receptor-stimulatory antibodies will be selected and used to substitute the cognate ligands. Thirdly, chimeric receptors will be constructed in which the cytoplasmic portion of the presumed receptor will be linked to an extracellular domain of an established receptor. This configuration will allow us to study the cellular consequences of receptor activation by using an available heterologous ligand. Yet, a fourth approach to receptor physiology will utilize natural mutants: A carcinogen-induced mutation of the neu gene that appears to mimic binding of the putative ligand, and mutations that apparently involve the kit gene (in W mutant mice) and yield stem cell diseases. These mutations will be examined biochemically or through bone-marrow transplantation to get independent insights into the function of each gene. Combinely, these studies are expected to yield the identification of new growth factors and provide a comprehensive picture of the cellular pathways elicited by them. In addition to the relevance to human adenocarcinomas (neu) granulocytic anemia and leukemia (kit) we hope that the presented study will pave conceptual and methodological ways towards functional studies of the many other receptor-like oncogenic proteins.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA051712-03
Application #
3196345
Study Section
Pathology B Study Section (PTHB)
Project Start
1990-05-01
Project End
1993-04-30
Budget Start
1992-05-15
Budget End
1993-04-30
Support Year
3
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Weizmann Institute of Science
Department
Type
DUNS #
City
Rehovot
State
Country
Israel
Zip Code
76100
Pinkas-Kramarski, R; Lenferink, A E; Bacus, S S et al. (1998) The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin. Oncogene 16:1249-58
Klapper, L N; Vaisman, N; Hurwitz, E et al. (1997) A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 14:2099-109
Levkowitz, G; Klapper, L N; Tzahar, E et al. (1996) Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene 12:1117-25
Pinkas-Kramarski, R; Shelly, M; Glathe, S et al. (1996) Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J Biol Chem 271:19029-32
Tzahar, E; Waterman, H; Chen, X et al. (1996) A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276-87
Marikovsky, M; Lavi, S; Pinkas-Kramarski, R et al. (1995) ErbB-3 mediates differential mitogenic effects of NDF/heregulin isoforms on mouse keratinocytes. Oncogene 10:1403-11
Gilboa, L; Ben-Levy, R; Yarden, Y et al. (1995) Roles for a cytoplasmic tyrosine and tyrosine kinase activity in the interactions of Neu receptors with coated pits. J Biol Chem 270:7061-7
Karunagaran, D; Tzahar, E; Liu, N et al. (1995) Neu differentiation factor inhibits EGF binding. A model for trans-regulation within the ErbB family of receptor tyrosine kinases. J Biol Chem 270:9982-90
Ben-Baruch, N; Yarden, Y (1994) Neu differentiation factors: a family of alternatively spliced neuronal and mesenchymal factors. Proc Soc Exp Biol Med 206:221-7
Ben-Levy, R; Paterson, H F; Marshall, C J et al. (1994) A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J 13:3302-11

Showing the most recent 10 out of 24 publications